

Anti-DLL3-PBD(Dar2)[Rovalpituzumab tesirine]

Product Information


Product Name	Anti-DLL3-PBD(Dar2)[Rovalpituzumab tesirine]
Storage temp.	Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
Catalog# / Size	GM-87847AB-100 / 100 µg GM-87847AB-1mg / 1 mg

Antibody Information

Expression System	CHO
Purity	> 95% as determined by SDS-PAGE
Aggregation	< 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR)	1.0-2.0
Endotoxin	<1EU/mg
Sterility	0.22 µm Filtered
Target	DLL3
Clone	Rovalpituzumab tesirine
Alternative Names	SCDO1
Source/Isotype	Monoclonal Human IgG1 (Delta 447K), kappa
Application	Positive control of Cytotoxicity Assay
Description	<p>Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed specifically to target diseases with high expression of DLL3 (Delta-like ligand 3), with a particular focus on small cell lung cancer (SCLC). The mechanism of action of Rova-T combines the high specificity of the antibody with the potent cytotoxicity of its payload. By targeting DLL3 on the surface of tumor cells, Rova-T delivers its anticancer drug payload directly into these cells. Once Rova-T binds to DLL3 and is internalized by the tumor cell, the toxic payload (such as tesirine) is released, where it attaches to and damages the tumor cell's DNA, causing double-strand breaks and ultimately triggering cell death. This design enables precise destruction of tumor cells while minimizing toxicity to normal tissues.</p>
Formulation	20 mM Histidine, 100 mM NaCl, pH 6.0


Version:3.1

SDS-PAGE





On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The purity of the protein is greater than 95%.

SEC-HPLC



The purity of this product is greater than 95% verified by SEC-HPLC.

HIC-HPLC



The drug-to-antibody ratio (DAR) of this product is 1.82